Recro

Sta Pharmaceutical, with locations in Shanghai, Tianjin, Wuhan, Chengdu, and Changzhou, is a leading pharmaceutical company specializing in small molecule API process development, formulation development and manufacturing, as well as oligonucleotide and peptide discovery and development. With state-of-the-art R&D labs and a fully integrated R&D and manufacturing campus, Sta Pharmaceutical offers a comprehensive range of services from preclinical to commercial manufacturing, providing efficient and high-quality solutions to global pharma and biotech customers. With a focus on delivering innovative medicinal chemistry solutions, Sta Pharmaceutical utilizes its discovery chemistry platform to create, identify, and support the discovery of preclinical candidates. The company also offers custom synthesis solutions for various molecules, including amidite, GalNAc, unnatural amino acids, and other peptide-related building blocks, to accelerate therapeutic development. With its expertise and capabilities, Sta Pharmaceutical is committed to advancing the pharmaceutical industry and meeting the needs of its clients.Generated from the website

BioTheryX, Inc. is a San Diego-based company specializing in the development of first-in-class protein degraders for the treatment of cancer and inflammatory diseases. With their PRODEGY Protein Degrader Technology platform, they are at the forefront of targeted protein degradation drug discovery, leveraging their expertise in modulating Cereblon to design unique and powerful drug candidates. Driven by their mission to degrade proteins and save lives, BioTheryX is building a pipeline of innovative protein degraders, including molecular glues and bifunctional degraders, with a focus on oncology and inflammatory disorders. Their groundbreaking research collaborations, preclinical findings, and participation in industry events demonstrate their commitment to transforming patient treatment through the development of novel therapies.Generated from the website

Belite Bio, Inc is a clinical stage biopharmaceutical drug development company based in San Diego, CA. They are focused on advancing novel therapies to address the unmet medical needs of patients suffering from blindness, liver disease, and diabetes, with a particular emphasis on retinal degenerative eye diseases such as atrophic age-related macular degeneration (AMD) and Stargardt disease. Their lead candidate, Tinlarebant, is a novel oral therapy designed to reduce the accumulation of toxins in the eye that cause these conditions. With a strong pipeline of therapies built on their RBP4 Retinol Binding Protein 4 IP Portfolio, Belite Bio is dedicated to bringing hope to those with incurable blindness and metabolic diseases. They have received Fast Track Designation, Rare Pediatric Disease designation, and Orphan Drug Designation for Tinlarebant, highlighting its potential as a groundbreaking treatment for Stargardt disease and Geographic Atrophy. Through their ongoing clinical trials, Belite Bio aims to provide effective and safe solutions for patients in need.Generated from the website